Search All Patents in Pandemics/Epidemics (Free)
Patent US10980756
Issued 2021-04-20
Methods Of Treatment
This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity (e.g., a chemical purity of greater than about 99.0%) or a particular particle size (e.g., a particular particle size distribution and/or a particular particle size range and/or a specific surface area range). In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for administration to the GI tract (e.g., orally or rectally such as via enema)).
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1. A method for treating a digestive symptom in a subject diagnosed as having a COVID-19 viral infection and in need of such treatment, the method comprising orally administering an effective amount of niclosamide: or a pharmaceutically acceptable salt thereof, to the subject; wherein the effective amount of niclosamide, or a pharmaceutically acceptable salt thereof, decreases an amount of COVID-19-viral RNA load in a fecal sample, an anal swab sample, or a rectal swab sample obtained from the subject by about 45% to about 99% relative to a baseline amount of COVID-19-viral RNA load, wherein the baseline amount of COVID-19 viral RNA load is an amount of COVID-19-related viral RNA that is present in a fecal sample, an anal swab sample, or a rectal swab sample obtained from the subject prior to administration of the niclosamide, or a pharmaceutically acceptable salt thereof.
- 22. A method for treating a subject having a COVID-19 viral infection and is in need of such treatment, the method comprising orally administering an effective amount of niclosamide: or a pharmaceutically acceptable salt thereof, to the subject so as to treat the COVID-19 viral infection; wherein the effective amount of niclosamide, or a pharmaceutically acceptable salt thereof, decreases an amount of COVID-19 viral RNA load in a fecal sample, an anal swab sample, or a rectal swab sample obtained from the subject by about 45% to about 99% relative to a baseline amount of COVID-19 viral RNA load, wherein the baseline amount of COVID-19 viral RNA load is an amount of COVID-19 viral RNA that is present in a fecal sample, an anal swab sample, or a rectal swab sample obtained from the subject prior to administration of the niclosamide, or a pharmaceutically acceptable salt thereof.
